AirSculpt Technologies, Inc., together with its subsidiaries, focuses on operating as a holding company for EBS Intermediate Parent LLC that provides body contouring procedure services in the United States and Canada. The company offers AirSculpt, a body contouring treatment that removes fat and tightens skin while sculpting targeted areas of the body in a minimally invasive procedure. It also provides AirSculpt+, a procedure that permanently removes fat and tightens the skin with unparalleled precision and finesse; and AirSculpt Smooth, an advanced cellulite removal tool. In addition, it provides fat removal procedures across treatment areas, such as the stomach, back, and buttocks; and fat transfer procedures that transfers the patient's own fat cells to enhance the buttocks, breasts, hips, aging hands, or other areas. Further, the company's body contouring procedures include the Power BBL, a Brazilian butt lift procedure; the Up a Cup, a breast enhancement procedure; and the Hip Flip, an hourglass contouring procedure. Additionally, it operates various centers. The company was founded in 2012 and is headquartered in Tampa, Florida.…
AirSculpt Technologies Announces First-Ever Nationwide Open House Event, "The Gift of Body Confidence"
AirSculpt Technologies (NASDAQ: AIRS) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Care Facilities industry, part of the Healthcare sector, and reports about 330 employees.
The shares were at 0.5907 USD on 20 November 2026, down 90.3% over 52 weeks. Its 52-week range is 0.5155 USD to 6.696 USD: the price is 91.2% below the high and 14.6% above the low.
Its market capitalisation is 43.67M USD.
AirSculpt Technologies reports return on equity of -13.3%, an operating margin of -4.9% and revenue down 8.7% year over year.
Its debt exceeds its cash by 49.84M USD, a debt-to-equity ratio of 0.95. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 3 analysts cover the stock, with an average rating of Buy; their mean price target of 1.333 USD is 125.7% above the current price. The next earnings report is expected on 16 March 2027.